# US 2022/0031841 A1 · Cancer associated antibody compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031841 A1
- Document ID: US20220031841A1
- Status: Published application
- Kind: A1
- Application number: 17/277,214
- Filed: 2019-09-19
- Published: 2022-02-03
- Earliest claimed: 2018-09-19
- Assignees: Totient, Inc.
- Applicants: Totient, Inc.
- Inventors: Daniele BIASCI; Ines de Santiago Domingos de JESUS; Berke Cagkan TOPTAS
- Web page: https://patentgrep.com/patent/US20220031841A1

## CPC

- A61K 39/39575: {against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants}
- C07K 16/3053: {Skin, nerves, brain}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/18: against material from animals or humans
- C07K 16/244: {Interleukins [IL]}
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- C07K 16/30: from tumour cells
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/40: against enzymes
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The disclosure herein relates to novel cancer-associated antibodies that are used in the treatment and diagnosis of a cancer. The complete polypeptide and nucleic acid consensus sequences of the antibodies disclosed herein are reconstructed in silico.

## Claims

### Claim 1

An antibody or antigen-binding fragment thereof comprising at least one of:
a complementarity-determining region heavy chain 1 (CDR-H1), a CDR-H2 and a CDR-H3, wherein the CDR-H1 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 85-98, the CDR-H2 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 57-70, and the CDR-H3 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 29-42.

### Claim 2

An antibody or antigen-binding fragment thereof that comprising at least one of:
a complementarity-determining region light chain 1 (CDR-L1), a CDR-L2 and a CDR-L3, wherein the CDR-L1 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 99-112, the CDR-L2 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 71-84, and the CDR-L3 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 43-56.

### Claim 3

An antibody or antigen-binding fragment thereof comprising:
a complementarity-determining region heavy chain 1 (CDR-H1), a CDR-H2 and a CDR-H3, wherein the CDR-H1 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 85-98, the CDR-H2 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 57-70, and the CDR-H3 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 29-42; and
a complementarity-determining region light chain 1 (CDR-L1), a CDR-L2 and a CDR-L3, wherein the CDR-L1 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 99-112, the CDR-L2 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 71-84, and the CDR-L3 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOS: 43-56.

### Claim 4 (depends on 1, 2, 3)

The antibody or antigen-binding fragment thereof of any one of claims 1-3, wherein the antibody is an IgG, IgA, or IgM antibody.

### Claim 5 (depends on 4)

The antibody or antigen-binding fragment thereof of claim 4, wherein the IgG is IgG1, IgG2, IgG3, IgG4, IgGA1, or IgGA2.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody or antigen-binding fragment thereof of any of claims 1-5, wherein the antibody is a chimeric antibody, a humanized antibody, a human antibody, a monoclonal antibody, a deimmunized antibody, a bispecific antibody, a multispecific antibody, or a combination thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The antibody or antigen-binding fragment thereof of any of claims 1-6, wherein the antibody is a monoclonal antibody.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The antibody or antigen-binding fragment thereof of any of claims 1-7, wherein the antibody is a multispecific antibody.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody or antigen-binding fragment thereof of any of claims 1-8, wherein the antibody is a multivalent antibody.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The antibody or antigen-binding fragment thereof of any one of claims 1-9, wherein the antigen-binding fragment comprises a Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′)2, a diabody, a linear antibody, a single domain antibodies (sdAb), a camelid VHH domain, or a multi-specific antibody formed from antibody fragments.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The antibody or antigen-binding fragment thereof of any one of claims 1-10, wherein the antibody or antigen-binding fragment thereof is recombinant or synthetic.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof further comprises an enzyme, a substrate, cofactor, a fluorescent marker, a chemiluminescent marker, a peptide tag, a magnetic particle, a drug, a toxin, a radionuclide, a binding site for secondary antibodies, a metal binding domain, or a combination thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The antibody or antigen-binding fragment thereof of any one of claims 1-12, wherein the antibody or antigen-binding fragment thereof is cytolytic to tumor cells or cancer cells.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The antibody or antigen-binding fragment thereof of any one of claims 1-13, wherein the antibody or antigen-binding fragment thereof inhibits tumor growth or cancer cell growth.

### Claim 15 (depends on 13, 14)

The antibody or antigen-binding fragment thereof of claim 13 or claim 14, that is useful for treating a skin cancer.

### Claim 16 (depends on 15)

The antibody or antigen-binding fragment thereof of claim 15, wherein the skin cancer is basal cell carcinoma, squamous cell carcinoma, cutaneous melanoma, merkel cell carcinoma, atypical fibroxanthoma, cutaneous lymphoma, or dermatofibrosarcoma.

### Claim 17

The antibody or antigen-binding fragment thereof, wherein the cutaneous melanoma is superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, subungual melanoma, lentigo maligna melanoma, desmoplastic melanoma, mucosal melanoma, or polypoid melanoma.

### Claim 18

An antibody or antigen-binding fragment thereof comprising:
(a) a variable heavy chain, wherein the variable heavy chain comprises a reconstructed polypeptide consensus sequence having at least 95% identity to an amino acid sequence selected from any one of SEQ ID NOS: 1-14;
(b) a variable light chain, wherein the variable light chain comprises a reconstructed polypeptide consensus sequence having at least 95% sequence identity to an amino acid sequence selected from any one of SEQ ID NOS: 15-28; or
(c) the variable heavy chain as in (a) and the variable light chain as in (b).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A hybridoma that produces the antibody or antigen-binding fragment thereof of any one of claims 1-18.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A fusion protein that comprises the antibody or antigen-binding fragment thereof of any one of claims 1-18.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A chimeric antigen receptor or a T cell receptor fusion protein that comprises:
(a) an antigen-binding fragment of any one of claims 1-18;
(b) a transmembrane domain; and
(c) an intracellular signaling domain.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A T cell receptor fusion protein that comprises:
(i) the antibody or antigen-binding fragment thereof of any one of claims 1-18, and
(ii) a T cell receptor (TCR) subunit.

### Claim 23 (depends on 22)

The T cell receptor fusion protein of claim 22, wherein the antibody or antigen binding fragment thereof comprises a human or humanized anti-cancer antigen binding domain.

### Claim 24 (depends on 22, 23)

The T cell receptor fusion protein of any one of claims 22-23, wherein the TCR subunit comprises;
(i) at least a portion of a TCR extracellular domain,
(ii) a transmembrane domain, and
(iii) a TCR intracellular domain comprising a stimulatory domain from an intracellular signaling domain.

### Claim 25 (depends on 24)

The T cell receptor fusion protein of claim 24, wherein the extracellular, the transmembrane, and the intracellular signaling domains of the TCR subunit are either derived from only CD3 epsilon or only CD3 gamma.

### Claim 26 (depends on 24, 25)

The T cell receptor fusion protein of any one of claims 24-25, wherein the antibody or antigen-binding fragment thereof and the TCR extracellular domain are connected by a linker sequence.

### Claim 27 (depends on 26)

The T cell receptor fusion protein of claim 26, wherein the linker sequence comprises the sequence of (G4S).n, wherein G is glycine, S is serine, and n=1 to 4.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

An isolated nucleic acid molecule encoding the T cell receptor fusion protein of any one of claims 21-27.

### Claim 29 (depends on 28)

A vector comprising the isolated nucleic acid molecule of claim 28.

### Claim 30 (depends on 28, 29)

A host cell comprising the isolated nucleic acid molecule of claim 28 or the vector of claim 29.

### Claim 31 (depends on 30)

The host cell of claim 30, wherein the host cell is a T cell.

### Claim 32 (depends on 21, 22, 23, 24, 25, 26, 27)

A T cell expressing the T cell receptor fusion protein of any one of claims 21-27.

### Claim 33 (depends on 32)

The T cell of claim 32, wherein the T cell receptor fusion protein is functionally integrated with an endogenous T cell receptor.

### Claim 34 (depends on 32, 33)

The T cell of any one of claims 32-33, wherein the T cell is a CD8+ or CD4+ T-cell.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

An immunoconjugate comprising the antibody or the antigen binding fragment thereof of any one of claims 1-18, and a therapeutic agent.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A pharmaceutical composition or a medicament comprising the antibody or antigen-binding fragment thereof of any one of claims 1-18 and a pharmaceutically acceptable carrier.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, further comprising a second therapeutic agent.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein the second therapeutic agent comprises an anti-cancer agent, a cytotoxic agent, a NSAID, a corticosteroid, a dietary supplement such as an antioxidant, or a combination thereof.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, wherein the anti-cancer agent is an anti-cancer antibody or a chemotherapeutic agent.

### Claim 40 (depends on 36, 37, 38, 39)

The pharmaceutical composition of any one of claims 36-39, formulated for administration via a subcutaneous, intravenous, intradermal, intraperitoneal, intramuscular, intracerebroventricular, intracranial, intracelial, or intracerebellar administration route.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The pharmaceutical composition of any one of claims 36-40, in an aqueous or in a lyophilized form.

### Claim 42 (depends on 36, 37, 38, 39, 40, 41)

The pharmaceutical composition of any one of claims 36-41, contained in a delivery device selected from the group consisting of a syringe, a blunt tip syringe, a catheter, and an implantable pump.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

Use of the antibody or antigen binding fragment of any one of claims 1-18 for treating a cancer.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 35)

Use of the antibody or antigen binding fragment thereof of any one of claims 1-18 or immunoconjugate of claim 35 in the manufacture of a medicament.

### Claim 45 (depends on 44)

The use of claim 44, wherein the medicament is for treatment of a cancer.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for treating a subject suffering from a cancer, the method comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-18.

### Claim 47 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof is cytolytic to tumor cells.

### Claim 48 (depends on 46, 47)

The method of claim 46 or claim 47, wherein the antibody or antigen-binding fragment thereof inhibits tumor growth.

### Claim 49 (depends on 46, 47, 48)

The method of any one of claims 46-48, wherein the cancer is skin cancer.

### Claim 50 (depends on 49)

The method of claim 49, wherein the skin cancer is basal cell carcinoma, squamous cell carcinoma, cutaneous melanoma, merkel cell carcinoma, atypical fibroxanthoma, cutaneous lymphoma, or dermatofibrosarcoma.

### Claim 51 (depends on 50)

The method of claim 50, wherein the cutaneous melanoma is superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, subungual melanoma, lentigo maligna melanoma, desmoplastic melanoma, mucosal melanoma, or polypoid melanoma.

### Claim 52 (depends on 46, 47, 48, 49, 50)

The method of any one of claims 46-50, wherein the antibody or antigen-binding fragment thereof is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially.

### Claim 53 (depends on 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 46-52, wherein the antibody or antigen-binding fragment thereof is administered to the subject in combination with a second therapeutic agent.

### Claim 54 (depends on 53)

The method of claim 53, wherein the second therapeutic agent comprises an anti-cancer agent, radiation therapy, a cytotoxic agent, a NSAID, a corticosteroid, a dietary supplement such as an antioxidant, or a combination thereof.

### Claim 55 (depends on 54)

The method of claim 54, wherein the anti-cancer agent is an anti-cancer antibody or a chemotherapeutic agent.

### Claim 56 (depends on 53, 54, 55)

The method of any one of claims 53-55, wherein the second therapeutic agent is administered prior to, concurrently, or after administering the antibody or antigen binding fragment.

### Claim 57

An isolated nucleic acid molecule comprising at least one of;
(a) a nucleic acid sequence encoding a CDR-H1, wherein the nucleic acid sequence is selected from SEQ ID NOS: 197-210;
(b) a nucleic acid sequence encoding a CDR-H2, wherein the nucleic acid sequence is selected from SEQ ID NOS: 169-182;
(c) a nucleic acid sequence encoding a CDR-H3, wherein the nucleic acid sequence is selected from SEQ ID NOS: 141-154;
(d) a nucleic acid sequence encoding a CDR-L1, wherein the nucleic acid sequence is selected from SEQ ID NOS: 211-224;
(e) a nucleic acid sequence encoding a CDR-L2, wherein the nucleic acid sequence is selected from SEQ ID NOS: 183-196; and
(f) a nucleic acid sequence encoding a CDR-L3, wherein the nucleic acid sequence is selected from SEQ ID NOS: 155-168.

### Claim 58

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a heavy chain polypeptide of an antibody, wherein the nucleic acid sequence is selected from any one of SEQ ID NOS:
113-126.

### Claim 59

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a light chain polypeptide of an antibody, wherein the nucleic acid sequence is selected from any one of SEQ ID NOS: 127-140.

### Claim 60 (depends on 57, 58, 59)

A vector comprising the isolated nucleic acid molecule of any one of claims 57-59.

### Claim 61 (depends on 60)

The vector of claim 60, wherein the isolated nucleic acid molecule is operably linked to a regulatory control sequence.

### Claim 62 (depends on 57, 58, 59, 60, 61)

A host cell comprising the vector of any one of claims 60-61 or the isolated nucleic acid molecule of any one of claims 57-59.

### Claim 63 (depends on 62)

A method of producing an antibody or an antigen binding fragment thereof, the method comprising:
(a) culturing the host cell of claim 62 in a medium under conditions permitting expression of a polypeptide encoded by the isolated nucleic acid molecule and assembling of the antibody or an antigen binding fragment thereof; and
(b) purifying the antibody or antigen binding fragment thereof from the cultured cell or the medium of the cell.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A kit comprising
(a) a therapeutically effective amount of at least one of the antibody or antigen binding fragment thereof of any one of claims 1-18.

### Claim 65

The kit further comprising a therapeutically effective amount of a second therapeutic agent.

### Claim 66 (depends on 65)

The kit of claim 65, wherein the second therapeutic agent is an anti-cancer agent, radiation therapy, a cytotoxic agent, a NSAID, a corticosteroid, a dietary supplement such as an antioxidant, or a combination thereof.

### Claim 67 (depends on 66)

The kit of claim 66, wherein the anti-cancer agent is an anti-cancer antibody or a chemotherapeutic agent.

### Claim 68 (depends on 64, 65, 66, 67)

The kit of any one of claims 64-67, wherein the antibody or antigen binding fragment thereof is in a lyophilized or an aqueous form.

### Claim 69 (depends on 64, 65, 66, 67, 68)

The kit of any one of claims 64-68, further comprising a reconstitution solution or a diluent.

### Claim 70

An antibody or an antigen binding fragment thereof that binds to a Src homology 2 (SH2) domain containing inositol polyphosphate 5-phosphatase 1 (SHIP1) protein or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO 85, CDR-H2 of SEQ ID NO: 57, and CDR-H3 of SEQ ID NO: 29;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO 99, CDR-L2 of SEQ ID NO: 71, and CDR-L3 of SEQ ID NO: 43; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 71 (depends on 70)

The antibody or antigen binding fragment thereof of claim 70, wherein the variable heavy chain comprises a polypeptide sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO 1, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO 15.

### Claim 72 (depends on 70, 71)

The antibody or antigen binding fragment thereof of any one of claims 70-71, wherein the antibody or antigen binding fragment thereof binds a human SHIP1, mouse SHIP1, rat SHIP1, bovine SHIP1, cynomolgus monkey SHIP1.

### Claim 73 (depends on 72)

The antibody or antigen binding fragment thereof claim 72, wherein the human SHIP1 comprises a sequence of SEQ ID NO: 281.

### Claim 74 (depends on 70, 71, 72)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 70-72 for binding to SHIP1, wherein the antibody binds to human SHIP1 and mouse SHIP1.

### Claim 75

An antibody or an antigen binding fragment thereof that binds to a Chromobox protein (CBX) or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 87, CDR-H2 of SEQ ID NO: 59, and CDR-H3 of SEQ ID NO: 31;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 101, CDR-L2 of SEQ ID NO: 73, and CDR-L3 of SEQ ID NO: 45; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 76 (depends on 75)

The antibody or antigen binding fragment thereof of claim 75, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 3, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17.

### Claim 77 (depends on 75, 76)

The antibody or antigen binding fragment thereof of any one of claims 75-76, wherein the antibody or antigen binding fragment thereof binds a human CBX, mouse CBX, rat CBX, bovine CBX, or cynomolgus monkey CBX.

### Claim 78 (depends on 75, 76, 77)

The antibody or antigen-binding fragment thereof any one of claims 75-77, wherein the chromobox (CBX) protein is Chromobox protein homolog 1, Chromobox protein homolog 3, or Chromobox protein homolog 5.

### Claim 79 (depends on 77, 78)

The antibody or antigen binding fragment thereof of claims 77-78, wherein the CBX protein is a human CBX 1 comprising a sequence of SEQ ID NO: 286.

### Claim 80 (depends on 77, 78)

The antibody or antigen binding fragment thereof of claims 77-78, wherein the CBX protein is a human CBX 3 comprising a sequence of SEQ ID NO: 291.

### Claim 81 (depends on 77, 78)

The antibody or antigen binding fragment thereof of claims 77-78, wherein the CBX protein is a human CBX 5 comprising a sequence of SEQ ID NO: 296.

### Claim 82 (depends on 75, 76, 77, 78, 79, 80, 81, 82)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 75-82 for binding to CBX protein, wherein the antibody binds to human CBX and mouse CBX.

### Claim 83

An antibody or an antigen binding fragment thereof that selectively binds to a Cancer/Testis Antigen 1B (CTAG1A) or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 89, CDR-H2 of SEQ ID NO: 61, and CDR-H3 of SEQ ID NO: 33;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 103, CDR-L2 of SEQ ID NO: 75, and CDR-L3 of SEQ ID NO: 47; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 84 (depends on 83)

The antibody or antigen binding fragment thereof of claim 83, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 5, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 19.

### Claim 85 (depends on 83, 84)

The antibody or antigen binding fragment thereof of any one of claims 83-84, wherein the antibody or antigen binding fragment thereof binds a human CTAG1A, mouse CTAG1A, rat CTAG1A, bovine CTAG1A, cynomolgus monkey CTAG1A.

### Claim 86 (depends on 85)

The antibody or antigen binding fragment thereof of claim 85, wherein the human CTAG1A comprises a sequence of SEQ ID NO: 301.

### Claim 87 (depends on 83, 84, 85, 86)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 83-86 for binding to CTAG1A, wherein the antibody binds to human CTAG1A and mouse CTAG1A.

### Claim 88

An antibody or an antigen binding fragment thereof that selectively binds to an Alpha and Gamma Adaptin Binding Protein (AAGAB) or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 90, CDR-H2 of SEQ ID NO: 62, and CDR-H3 of SEQ ID NO: 34;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 104, CDR-L2 of SEQ ID NO: 76, and CDR-L3 of SEQ ID NO: 48; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 89 (depends on 88)

The antibody or antigen binding fragment thereof of claim 88, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 6, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20.

### Claim 90 (depends on 88, 89)

The antibody or antigen binding fragment thereof of any one of claims 88-89, wherein the antibody or antigen binding fragment thereof binds a human AAGAB, mouse AAGAB, rat AAGAB, bovine AAGAB, cynomolgus monkey AAGAB.

### Claim 91 (depends on 90)

The antibody or antigen binding fragment thereof of claim 90, wherein the human AAGAB comprises a sequence of SEQ ID NO: 303.

### Claim 92 (depends on 88, 89, 90, 91)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 88-91 for binding to AAGAB, wherein the antibody binds to human AAGAB and mouse AAGAB.

### Claim 93

An antibody or an antigen binding fragment thereof that selectively binds to Kinesin light chain 4 protein (KLC4) or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 91, CDR-H2 of SEQ ID NO: 63, and CDR-H3 of SEQ ID NO: 35;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 105, CDR-L2 of SEQ ID NO: 77, and CDR-L3 of SEQ ID NO: 49; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 94 (depends on 93)

The antibody or antigen binding fragment thereof of claim 93, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 21.

### Claim 95 (depends on 93, 94)

The antibody or antigen binding fragment thereof of any one of claims 93-94, wherein the antibody or antigen binding fragment thereof binds a human KLC4, mouse KLC4, rat KLC4, bovine KLC4, cynomolgus monkey KLC4.

### Claim 96 (depends on 95)

The antibody or antigen binding fragment thereof of claim 95, wherein the human KLC4 comprises a sequence of SEQ ID NO: 308.

### Claim 97 (depends on 93, 94, 95, 96)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 93-96 for binding to KLC4, wherein the antibody binds to human KLC4 and mouse KLC4.

### Claim 98

An antibody or an antigen binding fragment thereof that selectively binds to Melanoma-associated antigen 3 (MAGE-A3) or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 92, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 36;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 106, CDR-L2 of SEQ ID NO: 78, and CDR-L3 of SEQ ID NO: 50; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 99 (depends on 98)

The antibody or antigen binding fragment thereof of claim 98, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 22.

### Claim 100 (depends on 98, 99)

The antibody or antigen binding fragment thereof of any one of claims 98-99, wherein the antibody or antigen binding fragment thereof binds a human MAGE-A3, mouse MAGE-A3, rat MAGE-A3, bovine MAGE-A3, cynomolgus monkey MAGE-A3.

### Claim 101 (depends on 100)

The antibody or antigen binding fragment thereof of claim 100, wherein the human MAGE-A3 comprises a sequence of SEQ ID NO: 313.

### Claim 102 (depends on 98, 99, 100, 101)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 98-101 for binding to MAGE-A3, wherein the antibody binds to human MAGE-A3 and mouse MAGE-A3.

### Claim 103

An antibody or an antigen binding fragment thereof that selectively binds to Inorganic pyrophosphatase (PPA1) or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 94, CDR-H2 of SEQ ID NO: 66, and CDR-H3 of SEQ ID NO: 38;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 108, CDR-L2 of SEQ ID NO: 80, and CDR-L3 of SEQ ID NO: 52; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 104 (depends on 103)

The antibody or antigen binding fragment thereof of claim 103, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24.

### Claim 105 (depends on 103, 104)

The antibody or antigen binding fragment thereof of any one of claims 103-104, wherein the antibody or antigen binding fragment thereof binds a human PPA1, mouse PPA1, rat PPA1, bovine PPA1, cynomolgus monkey PPA1.

### Claim 106 (depends on 105)

The antibody or antigen binding fragment thereof of claim 105, wherein the human PPA1 comprises a sequence of SEQ ID NO: 315.

### Claim 107 (depends on 103, 104, 105, 106)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 103-106 for binding to PPA1, wherein the antibody binds to human PPA1 and mouse PPA1.

### Claim 108

An antibody or an antigen binding fragment thereof that selectively binds to interleukin-14A (IL-14A) or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 95, CDR-H2 of SEQ ID NO: 67, and CDR-H3 of SEQ ID NO: 39;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 109, CDR-L2 of SEQ ID NO: 81, and CDR-L3 of SEQ ID NO: 53; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 109 (depends on 108)

The antibody or antigen binding fragment thereof of claim 108, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25.

### Claim 110 (depends on 108, 109)

The antibody or antigen binding fragment thereof of any one of claims 108-109, wherein the antibody or antigen binding fragment thereof binds a human IL-14A, mouse IL-14A, rat IL-14A, bovine IL-14A, cynomolgus monkey IL-14A.

### Claim 111 (depends on 110)

The antibody or antigen binding fragment thereof of claim 110, wherein the human IL-14A comprises a sequence of SEQ ID NO: 319.

### Claim 112 (depends on 108, 109, 110, 111)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 108-111 for binding to IL-14A, wherein the antibody binds to human IL-14A and mouse IL-14A.

### Claim 113

An antibody or an antigen binding fragment thereof that selectively binds to O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) or a variant thereof, comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 98, CDR-H2 of SEQ ID NO: 70, and CDR-H3 of SEQ ID NO: 42;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 112, CDR-L2 of SEQ ID NO: 84, and CDR-L3 of SEQ ID NO: 56; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 114 (depends on 113)

The antibody or antigen binding fragment thereof of claim 113, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 14, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 28.

### Claim 115 (depends on 113, 114)

The antibody or antigen binding fragment thereof of any one of claims 113-114, wherein the antibody or antigen binding fragment thereof binds a human OGT, mouse OGT, rat OGT, bovine OGT, cynomolgus monkey OGT.

### Claim 116 (depends on 115)

The antibody or antigen binding fragment thereof of claim 115, wherein the human OGT comprises a sequence of SEQ ID NO: 324.

### Claim 117 (depends on 113, 114, 115, 116)

An antibody that competes with an antibody or antigen binding fragment of any one of claims 113-116 for binding to OGT, wherein the antibody binds to human OGT and mouse OGT.

### Claim 118 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

An immunohistochemical assay comprising;
(a) contacting a sample with the antibody or antigen binding fragment thereof of any one of claims 1-18 under conditions permitting selective binding of the antibody or antigen binding fragment thereof with an antigen, to form an antibody-antigen complex;
(b) detecting the presence or absence of the antibody-antigen complex by an immunodetection method.

### Claim 119 (depends on 118)

The immunohistochemical assay of claim 118, wherein the sample is a blood sample or a tissue sample.

### Claim 120 (depends on 118, 119)

The immunohistochemical assay of claim 118 or claim 119, wherein the sample is from a subject suspected to be suffering from cancer or diagnosed with cancer.

### Claim 121 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating a Src homology 2 (SH2) domain containing inositol polyphosphate 5-phosphatase 1 (SHIP1) related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 122 (depends on 121)

The method of claim 121, wherein the antibody or antigen binding fragment thereof comprises at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO 85, CDR-H2 of SEQ ID NO: 57, and CDR-H3 of SEQ ID NO: 29;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO 99, CDR-L2 of SEQ ID NO: 71, and CDR-L3 of SEQ ID NO: 43; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 123 (depends on 122)

The method of claim 122, wherein the variable heavy chain comprises a polypeptide sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO 1, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO 15.

### Claim 124 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating a Chromobox protein (CBX) or a variant thereof related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 125 (depends on 124)

The method of claim 124, wherein the antibody or antigen binding fragment thereof comprises at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 87, CDR-H2 of SEQ ID NO: 59, and CDR-H3 of SEQ ID NO: 31;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 101, CDR-L2 of SEQ ID NO: 73, and CDR-L3 of SEQ ID NO: 45; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 126 (depends on 125)

The method of claim 125, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 3, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17.

### Claim 127 (depends on 124, 125, 126)

The method of any one of claims 124-126, wherein the chromobox protein (CBX) is Chromobox protein homolog 1, Chromobox protein homolog 3, or Chromobox protein homolog 5.

### Claim 128 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating a Cancer/Testis Antigen 1B (CTAG1A) thereof related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 129 (depends on 128)

The method of claim 128, wherein the antibody or antigen binding fragment thereof comprises at least one of at least one of:
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 89, CDR-H2 of SEQ ID NO: 61, and CDR-H3 of SEQ ID NO: 33;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 103, CDR-L2 of SEQ ID NO: 75, and CDR-L3 of SEQ ID NO: 47; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 130 (depends on 129)

The method of claim 129, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 5, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 19.

### Claim 131 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating an Alpha and Gamma Adaptin Binding Protein (AAGAB) thereof related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 132 (depends on 131)

The method of claim 131, wherein the antibody or antigen binding fragment thereof comprises at least one of comprising at least one of
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 90, CDR-H2 of SEQ ID NO: 62, and CDR-H3 of SEQ ID NO: 34;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 104, CDR-L2 of SEQ ID NO: 76, and CDR-L3 of SEQ ID NO: 48; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 133 (depends on 132)

The method of claim 132, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 6, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20.

### Claim 134 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating an Kinesin light chain 4 protein (KLC4) thereof related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 135 (depends on 134)

The method of claim 134, wherein the antibody or antigen binding fragment thereof comprises at least one of comprising at least one of:
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 91, CDR-H2 of SEQ ID NO: 63, and CDR-H3 of SEQ ID NO: 35;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 105, CDR-L2 of SEQ ID NO: 77, and CDR-L3 of SEQ ID NO: 49; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 136 (depends on 135)

The method of claim 135, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 21.

### Claim 137 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating Melanoma-associated antigen 3 (MAGE-A3) thereof related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 138 (depends on 137)

The method of claim 137, wherein the antibody or antigen binding fragment thereof comprises at least one of comprising at least one of:
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 92, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 36;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 106, CDR-L2 of SEQ ID NO: 78, and CDR-L3 of SEQ ID NO: 50; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 139 (depends on 138)

The method of claim 138, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 22.

### Claim 140 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating Inorganic pyrophosphatase (PPA1) thereof related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 141 (depends on 140)

The method of claim 140, wherein the antibody or antigen binding fragment thereof comprises at least one of comprising at least one of:
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 94, CDR-H2 of SEQ ID NO: 66, and CDR-H3 of SEQ ID NO: 38;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 108, CDR-L2 of SEQ ID NO: 80, and CDR-L3 of SEQ ID NO: 52; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 142 (depends on 141)

The method of claim 141, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24.

### Claim 143 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating interleukin-14A (IL-14A) thereof related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 144 (depends on 143)

The method of claim 143, wherein the antibody or antigen binding fragment thereof comprises at least one of comprising at least one of:
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 95, CDR-H2 of SEQ ID NO: 67, and CDR-H3 of SEQ ID NO: 39;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 109, CDR-L2 of SEQ ID NO: 81, and CDR-L3 of SEQ ID NO: 53; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 145 (depends on 144)

The method of claim 144, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25.

### Claim 146 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method for diagnosing or treating O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) thereof related condition in a cell, tissue, organ or subject comprising:
contacting or administering an effective amount of at least one antibody or antigen binding fragment thereof of any one of claims 1-18, with or to, the cell, tissue, organ or subject.

### Claim 147 (depends on 146)

The method of claim 146, wherein the antibody or antigen binding fragment thereof comprises at least one of comprising at least one of:
(a) a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 98, CDR-H2 of SEQ ID NO: 70, and CDR-H3 of SEQ ID NO: 42;
(b) a variable light chain region, wherein the variable light chain region comprises a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 112, CDR-L2 of SEQ ID NO: 84, and CDR-L3 of SEQ ID NO: 56; or
(c) the variable heavy chain of (a) and the variable light chain of (b).

### Claim 148 (depends on 147)

The method of claim 147, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 14, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 28.
